Edwards Lifesciences Corp. (EW) announced this weekend that its PARTNER II Trial, comparing the SAPIEN XT valve to surgery in intermediate-risk patients, successfully met its primary endpoint.
from RTT - Before the Bell http://ift.tt/1MaNWaM
via IFTTT
No comments:
Post a Comment